With around 450 attendees, the five-day digital conference particularly focused on market conditions and financing. SMEs and global partners urged for more pull incentives.
Swiss BioVersys AG has secured a CHF19m Series B financing to push clinincal development of two antiinfectives against drug-resistant pathogens.
PPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.
Polyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China.
British fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
US experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
Roche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19.
Antinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.